SBIR/STTR Research Award
Prevention of Pseudomonas Infection with anti-PcrV
Award amount
$100,000Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- INTERMUNE PHARMACEUTICALS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): We propose an innovative approach to
prevent Pseudomonas aeruginosa infection by blockade of a critical Type III
secretory protein with monoclonal antibodies. Pseudomonas causes disease by the
release of exotoxins which destroy host tissue and paralyze the phagocytic
mechanism of macrophages. To be active, many toxins require translocation from
the interior of the bacteria directly into the eukaryotic cell. This
translocation (type Ill secretory mechanism) is accomplished by a group of
proteins which form a channel from the interior of the bacterium to the
interior of the host cell. Preliminary work has shown that one of the type Ill
secretory proteins, PcrV, is critical for translocation of toxins into the host
cell. Blockade of this protein with active immunization or passive immunization
with polyclonal antibodies prevents infection with P. aeruginosa in a murine
model of pneumonitis. The overall goal of this Phase I proposal is to develop a
murine monoclonal antibody to PcrV to prevent infection with P. aeruginosa.
This work should establish proof of principle that a monoclonal antibody to
PcrV can prevent infection, thus supporting the development of human monoclonal
antibodies as a preventive therapy in patients at high risk for P. aeruginosa
infection.
PROPOSED COMMERCIAL APPLICATION:
Pseudomonas aeruginasa is a major cause of hospital-acquired infection, accounting for 20% of nosocomial pneumonias,10-15% of nosocomial urinary tract infections and 10% of sepsis. In addition, P. aeruginosa infection is the major cause of mortality in cystic fibrosis. Current treatment is associated with a high rate of antibiotic resistance and a 25-50% failure rate. The proposed treatment provides a novel approach to the prevention of P. aervginosa infection in patients at high risk for this infection, including patients on ventilators, bum patients, patients with in-dwelling catheters, neutropenic patients, and patients with cystic fibrosis.
Technology keywords
Not reported